Thousands of people with common conditions that make breathing a struggle could be getting more support from the Government.

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

T-Mobile US Inc. has rolled back policies related to diversity, equity, and inclusion to appease the chairman of the Federal ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

A new study reveals that our organs age at different speeds, and those differences can predict future disease risk and even ...

Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC. The deal adds Verona ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...